These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 17428867)

  • 21. Vinexin β Interacts with Hepatitis C Virus NS5A, Modulating Its Hyperphosphorylation To Regulate Viral Propagation.
    Xiong W; Yang J; Wang M; Wang H; Rao Z; Zhong C; Xin X; Mo L; Yu S; Shen C; Zheng C
    J Virol; 2015 Jul; 89(14):7385-400. PubMed ID: 25972535
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Conserved determinants for membrane association of nonstructural protein 5A from hepatitis C virus and related viruses.
    Brass V; Pal Z; Sapay N; Deléage G; Blum HE; Penin F; Moradpour D
    J Virol; 2007 Mar; 81(6):2745-57. PubMed ID: 17192310
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HCV core residues critical for infectivity are also involved in core-NS5A complex formation.
    Gawlik K; Baugh J; Chatterji U; Lim PJ; Bobardt MD; Gallay PA
    PLoS One; 2014; 9(2):e88866. PubMed ID: 24533158
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of Membrane Stretch in Adsorption of Antiviral Peptides onto Lipid Membranes and Membrane Pore Formation.
    Chng CP; Cho NJ; Hsia KJ; Huang C
    Langmuir; 2021 Nov; 37(45):13390-13398. PubMed ID: 34724382
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Creation of lipid partitions by deposition of amphipathic viral peptides.
    Cho NJ; Cho SJ; Hardesty JO; Glenn JS; Frank CW
    Langmuir; 2007 Oct; 23(21):10855-63. PubMed ID: 17803321
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Testing the modularity of the N-terminal amphipathic helix conserved in picornavirus 2C proteins and hepatitis C NS5A protein.
    Teterina NL; Gorbalenya AE; Egger D; Bienz K; Rinaudo MS; Ehrenfeld E
    Virology; 2006 Jan; 344(2):453-67. PubMed ID: 16226781
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Domain 3 of NS5A protein from the hepatitis C virus has intrinsic alpha-helical propensity and is a substrate of cyclophilin A.
    Verdegem D; Badillo A; Wieruszeski JM; Landrieu I; Leroy A; Bartenschlager R; Penin F; Lippens G; Hanoulle X
    J Biol Chem; 2011 Jun; 286(23):20441-54. PubMed ID: 21489988
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Proprotein convertase subtilisin/kexin type 9 inhibits hepatitis C virus replication through interacting with NS5A.
    Li Z; Liu Q
    J Gen Virol; 2018 Jan; 99(1):44-61. PubMed ID: 29235977
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Human Choline Kinase-α Promotes Hepatitis C Virus RNA Replication through Modulation of Membranous Viral Replication Complex Formation.
    Wong MT; Chen SS
    J Virol; 2016 Oct; 90(20):9075-95. PubMed ID: 27489281
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cortactin Interacts with Hepatitis C Virus Core and NS5A Proteins: Implications for Virion Assembly.
    Nguyen LP; Nguyen TTT; Nguyen HC; Pham HT; Han KM; Choi DH; Park EM; Kang SM; Tark D; Lim YS; Hwang SB
    J Virol; 2020 Sep; 94(19):. PubMed ID: 32727880
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rab18 binds to hepatitis C virus NS5A and promotes interaction between sites of viral replication and lipid droplets.
    Salloum S; Wang H; Ferguson C; Parton RG; Tai AW
    PLoS Pathog; 2013; 9(8):e1003513. PubMed ID: 23935497
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Human VAP-B is involved in hepatitis C virus replication through interaction with NS5A and NS5B.
    Hamamoto I; Nishimura Y; Okamoto T; Aizaki H; Liu M; Mori Y; Abe T; Suzuki T; Lai MM; Miyamura T; Moriishi K; Matsuura Y
    J Virol; 2005 Nov; 79(21):13473-82. PubMed ID: 16227268
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interaction between the NS4B amphipathic helix, AH2, and charged lipid headgroups alters membrane morphology and AH2 oligomeric state--Implications for the Hepatitis C virus life cycle.
    Ashworth Briggs EL; Gomes RG; Elhussein M; Collier W; Findlow IS; Khalid S; McCormick CJ; Williamson PT
    Biochim Biophys Acta; 2015 Aug; 1848(8):1671-7. PubMed ID: 25944559
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Daclatasvir-like inhibitors of NS5A block early biogenesis of hepatitis C virus-induced membranous replication factories, independent of RNA replication.
    Berger C; Romero-Brey I; Radujkovic D; Terreux R; Zayas M; Paul D; Harak C; Hoppe S; Gao M; Penin F; Lohmann V; Bartenschlager R
    Gastroenterology; 2014 Nov; 147(5):1094-105.e25. PubMed ID: 25046163
    [TBL] [Abstract][Full Text] [Related]  

  • 35. GPS2 is required for the association of NS5A with VAP-A and hepatitis C virus replication.
    Xu G; Xin X; Zheng C
    PLoS One; 2013; 8(11):e78195. PubMed ID: 24223774
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interactions between Viperin, Vesicle-Associated Membrane Protein A, and Hepatitis C Virus Protein NS5A Modulate Viperin Activity and NS5A Degradation.
    Ghosh S; Patel AM; Grunkemeyer TJ; Dumbrepatil AB; Zegalia K; Kennedy RT; Marsh ENG
    Biochemistry; 2020 Feb; 59(6):780-789. PubMed ID: 31977203
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The interaction between the hepatitis C proteins NS4B and NS5A is involved in viral replication.
    David N; Yaffe Y; Hagoel L; Elazar M; Glenn JS; Hirschberg K; Sklan EH
    Virology; 2015 Jan; 475():139-49. PubMed ID: 25462354
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hepatitis C virus RNA polymerase and NS5A complex with a SNARE-like protein.
    Tu H; Gao L; Shi ST; Taylor DR; Yang T; Mircheff AK; Wen Y; Gorbalenya AE; Hwang SB; Lai MM
    Virology; 1999 Oct; 263(1):30-41. PubMed ID: 10544080
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The C-terminal alpha-helix domain of apolipoprotein E is required for interaction with nonstructural protein 5A and assembly of hepatitis C virus.
    Cun W; Jiang J; Luo G
    J Virol; 2010 Nov; 84(21):11532-41. PubMed ID: 20719944
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hepatitis C virus NS5A disrupts STAT1 phosphorylation and suppresses type I interferon signaling.
    Kumthip K; Chusri P; Jilg N; Zhao L; Fusco DN; Zhao H; Goto K; Cheng D; Schaefer EA; Zhang L; Pantip C; Thongsawat S; O'Brien A; Peng LF; Maneekarn N; Chung RT; Lin W
    J Virol; 2012 Aug; 86(16):8581-91. PubMed ID: 22674974
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.